Pitavastatin Calcium
(Synonyms: 匹伐他汀钙; NK-104 hemicalcium; Pitavastatin hemicalcium) 目录号 : GC12116
An HMG-CoA reductase inhibitor
Cas No.:147526-32-7
Sample solution is provided at 25 µL, 10mM.
| Cell experiment [1]: | |
|
Cell lines |
Huh-7 and SMMC7721 liver cancer cell lines |
|
Preparation method |
The solubility of this compound in DMSO is >34.9mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0-20 μM |
|
Applications |
In the liver cancer Huh-7 cells and SMMC7721 cells, pitavastatin inhibited cell growth in a dose-dependent way and inhibited colony formation. Pitavastatin significantly arrested the Huh-7 cells at the G1 phase and increased the proportion of sub-G1 phase cells. Pitavastatin induced apoptosis dependent of caspases. |
| Animal experiment [2]: | |
|
Animal models |
Experimental autoimmune myocarditis (EAM) BALB/c mice |
|
Dosage form |
5 mg/kg; 3 weeks from day 0 to day 21; orally |
|
Application |
In experimental autoimmune myocarditis (EAM) BALB/c mice, pitavastatin reduced the pathophysiological severity of the myocarditis. Pitavastatin inhibited the phosphorylation of STAT3 and STAT4, and suppressed production of Th1 cytokine interferon-γ and Th17 cytokine interleukin-17 from autoreactive CD4+T cells in the heart. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] You HY1, Zhang WJ1, Xie XM1, et al. Pitavastatin suppressed liver cancer cells in vitro and in vivo. Onco Targets Ther. 2016 Aug 29;9:5383-8. [2]. Tajiri K1, Shimojo N, Sakai S, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther. 2013 Oct;27(5):413-24. | |
| Cas No. | 147526-32-7 | SDF | |
| 别名 | 匹伐他汀钙; NK-104 hemicalcium; Pitavastatin hemicalcium | ||
| 化学名 | calcium;(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate | ||
| Canonical SMILES | C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)[O-])O)O)C4=CC=C(C=C4)F.C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)[O-])O)O)C4=CC=C(C=C4)F.[Ca+2] | ||
| 分子式 | C50H46CaF2N2O8 | 分子量 | 880.98 |
| 溶解度 | ≥ 34.85mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1351 mL | 5.6755 mL | 11.351 mL |
| 5 mM | 0.227 mL | 1.1351 mL | 2.2702 mL |
| 10 mM | 0.1135 mL | 0.5675 mL | 1.1351 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet